We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
-20.83%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$803M
AUM Growth
-$319M
Cap. Flow
-$34M
Cap. Flow %
-4.24%
Top 10 Hldgs %
60.78%
Holding
78
New
17
Increased
17
Reduced
12
Closed
19

Top Buys

Rank Stock Value
1
NCNA
NuCana
NCNA
+$28.4M
2
GILD icon
Gilead Sciences
GILD
+$14.9M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.4M
4
INCY icon
Incyte
INCY
+$12.2M
5
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$9.65M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$61.6M
2
AGN
Allergan plc
AGN
+$18.3M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$9.09M
4
APLS
Apellis Pharmaceuticals
APLS
+$7.67M
5
EXEL icon
Exelixis
EXEL
+$7.15M

Sector Composition

Rank Sector Weight
1 Healthcare 91.28%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.7B
$93.9M 11.7%
1,498,538
-980,976
-40% -$61.6M
AMRN
2
Amarin Corp
AMRN
$284M
$70.9M 8.83%
260,415
– –
OBSV
3
DELISTED
ObsEva SA Ordinary Shares
OBSV
$60.1M 7.49%
4,749,623
– –
PRNB
4
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$55.8M 6.95%
2,038,208
-20,938
-1% -$540K
NTRA icon
5
Natera
NTRA
$37.5B
$43.3M 5.39%
3,100,560
– –
YMAB
6
DELISTED
Y-mAbs Therapeutics
YMAB
$42.8M 5.33%
2,104,278
– –
NCNA
7
NuCana
NCNA
$5.37M
$32.9M 4.09%
453
+320
+241% +$28.4M
MRUS
8
DELISTED
Merus
MRUS
$27.5M 3.42%
1,961,039
– –
CHRS icon
9
Coherus Oncology
CHRS
$217M
$26M 3.23%
2,868,221
– –
KNSA icon
10
Kiniksa Pharmaceuticals
KNSA
$4.83B
$25.9M 3.23%
922,700
– –
BOLD
11
DELISTED
Audentes Therapeutics, Inc
BOLD
$19.9M 2.48%
933,640
– –
ONCE
12
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$18.8M 2.35%
481,270
– –
SNY icon
13
Sanofi
SNY
$104B
$14.2M 1.77%
327,175
-85,571
-21% -$3.77M
ACRS icon
14
Aclaris Therapeutics
ACRS
$730M
$14.1M 1.76%
1,911,573
+372,093
+24% +$3.84M
GILD icon
15
Gilead Sciences
GILD
$161B
$13.3M 1.66%
+213,331
New +$14.9M
AZN icon
16
AstraZeneca
AZN
$263B
$12M 1.5%
158,164
+37,860
+31% +$2.96M
INCY icon
17
Incyte
INCY
$23.5B
$12M 1.49%
+188,497
New +$12.2M
BMRN icon
18
BioMarin Pharmaceuticals
BMRN
$11.5B
$12M 1.49%
+140,542
New +$13.4M
TSRO
19
DELISTED
TESARO, Inc.
TSRO
$9.97M 1.24%
134,297
-89,378
-40% -$4.3M
HRTX icon
20
Heron Therapeutics
HRTX
$86.3M
$9.33M 1.16%
359,713
+64,124
+22% +$1.76M
RETA
21
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$8.86M 1.1%
+157,984
New +$9.65M
ITRM
22
DELISTED
Iterum Therapeutics
ITRM
$8.65M 1.08%
115,101
– –
RIGL icon
23
Rigel Pharmaceuticals
RIGL
$680M
$7.78M 0.97%
338,217
+12,124
+4% +$342K
XNCR icon
24
Xencor
XNCR
$1.44B
$7.22M 0.9%
+199,682
New +$7.33M
FOLD
25
DELISTED
Amicus Therapeutics
FOLD
$6.46M 0.81%
674,636
+228,667
+51% +$2.51M
1
2 3

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q4 2018 Portfolio in Review

As of Q4 2018, Sofinnova Investments held 78 positions worth $803M, down 28% from $1.12B the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Sofinnova Investments withdrew a net $34M in Q4 2018, closing 19 positions and reducing 12 holdings. Its most notable exit was Allergan plc, an estimated $18.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 86% a quarter earlier.

Against the trend, Sofinnova Investments opened a new position in Gilead Sciences worth $13.3M.

  • Sofinnova Investments's largest Q4 2018 buy was Gilead Sciences: 213,331 shares worth $13.3M.
  • Sofinnova Investments added most to NuCana in Q4 2018, an estimated $28.4M increase.
  • Sofinnova Investments's biggest Q4 2018 reduction was Ascendis Pharma A/S, cutting an estimated $61.6M.
  • Sofinnova Investments fully exited Allergan plc in Q4 2018, selling an estimated $18.3M.
  • Sofinnova Investments's ten largest holdings make up 61% of its $803M portfolio in Q4 2018.
  • Sofinnova Investments opened 17 new positions and closed 19 in Q4 2018.
  • Sofinnova Investments's portfolio value fell 28% quarter-over-quarter to $803M.

Based on Sofinnova Investments's 13F filing for Q4 2018, filed 14 Feb 2019.